close

Agreements

1 2 3 4 5 248
Number of results: 4941

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2018-10-03 Cellular Biomedicine Group (China) National Cancer Institute (USA) next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology licensing Cancer - Oncology Licensing agreement
2018-10-03 Be The Match BioTherapies®(USA - MIN) Cryoport (USA - CA) end-to-end supply chain services to the cell and gene therapy industry collaboration Technology - Services Collaboration agreement
2018-10-03 Denali Therapeutics (USA - CA) Centogene (Germany) LRRK2 mutation carrier Parkinson’s disease patients Parkinson's disease collaboration Neurodegenerative diseases Collaboration agreement
2018-10-02 Cytosen Therapeutics (USA - TX) KBI Biopharma (USA - NC) Natural Killer (NK) cells bioproduction - manufacturing Cancer - Oncology - Technology - Services Production agreement
2018-10-02 Kite Pharma (USA - CA), a Gilead company (USA - CA) HiFiBiO Therapeutics (USA - MA) neoantigen-reactive T cell receptors (TCRs) for the treatment of various cancers research - licensing Cancer - Oncology Licensing agreement
2018-10-01 Editas Medicine (USa - MA) senior vice president nomination Rare diseases - Genetic diseases - Ophtalmological diseases Nomination
2018-10-01 Melinta Therapeutics (USA - CT) Menarini (Italy) Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible designated gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia, bacteraemia that occurs in association with any of these infections and infections due to aerobic Gram-negative organisms, infections due to susceptible strains of important designated gram-positive and gram-negative pathogens, including infections due to Acinetobacter species licensing - development - commercialisation Infectious diseases Licensing agreement
2018-10-01 KangStem Biotech (South Korea) MaSTherCell, (Belgium), a subsidiary of Orgenesis (USA - NY) Furestem-AD® manufacturing - bioproduction Technology - Services Production agreement
2018-09-27 Editas Medicine (USA - MA) chief medical officer resignation Rare diseases - Genetic diseases - Ophtalmological diseases Resignation
2018-09-27 Cellular Biomedicine Group (China) Novartis (Switzerland) Kymriah® - CTL019 (tisagenlecleucel-T) manufacturing - production Cancer - Oncology - Technology - Services Production agreement
2018-09-27 Cellular Biomedicine Group (China) Novartis (Switzerland) Kymriah® - CTL019 (tisagenlecleucel-T) manufacturing - production Cancer - Oncology - Technology - Services Production agreement
2018-09-27 Allogene Therapeutics (USA - CA) member of the board of directors nomination Cancer - Oncology Nomination
2018-09-27 BioInvent (Sweden) Cardiovax (USA - CA) orticumab (BI-204) production - manufacturing Inflammatory diseases - Technology Services Production agreement
2018-09-27 SQZ Biotech (USA - MA) nomination Cancer - Oncology - Metabolic diseases Nomination
2018-09-26 Celyad (Belgium) vice president nomination Cancer - Oncology Nomination
2018-09-25 Cobra Biologics (Sweden) Centre for Process Innovation (CPI) (UK) GE Healthcare Life Sciences (USA - WI) manufacturing of adeno-associated virus (AAV) vectors collaboration Technology - Services Collaboration agreement
2018-09-25 KSQ Therapeutics (USA - MA) member of the board of directors nomination Cancer - Oncology Nomination
2018-09-21 InflaRx (Germany) member of the board nomination Inflammatory diseases Nomination
2018-09-21 Arcturus Therapeutics (USA - CA) vice-president nomination Nomination
2018-09-20 Celltrion Healthcare (South Korea) Emory University (USA - GA) new drug candidates for atherosclerosis atherosclerosis development Cardiovascular diseases Development agreement